A coding-length clone of rat liver fructose-1,6-bisphosphatase (EC 3.1.3.11) was isolated by immunological screening of a cDNA library in Agtll. Its identity was verified by comparing the deduced amino acid sequence with that obtained by direct sequencing of a complete set of CNBr and proteolytic peptides from the purified protein. The enzyme subunit is composed of 362 amino acids and has N-acetylvaline as the amino-terminal residue. The cDNA, 1255 base pairs (bp) long, consisted of 1086 bp of coding region, 15 bp of 5' untranslated sequence, and 154 bp at the 3' untranslated end. The 3' untranslated sequence contained a polyadenylylation signal (AATAAA) followed after 30 bp by a stretch of 7 adenines at the end of the clone. The deduced amino acid sequence was identical to the primary sequence of the protein and confirmed the alignment of five nonoverlapping peptides. It also confirmed the 27-residue extension, unique to the rat liver subunit, ending with a carboxyl-terminal phenylalanine. RNA blot analyses using the radiolabeled liver cDNA as a probe revealed a single band of fructose-1,6-bisphosphatase mRNA, 1.4 kilobases long, in liver and kidney but not in nongluconeogenic tissues. Fructose-1,6-bisphosphatase mRNA was increased 10-fold in livers from diabetic rats and was reduced to control levels after 24 hr of insulin treatment, suggesting that the changes in enzyme activity observed in diabetes and after insulin treatment are due to alterations in mRNA abundance.
bisphosphate (Fru-2,6-P2) (2, 3) , which has been postulated to bind either to the active site (2, 4) or to a separate allosteric site (3, 5) . Most of the studies on allosteric regulation of Fru-1,6-P2ase by Fru-2,6-P2 have been carried out on the rat liver enzyme, but identification ofthe Fru -2,6-P2 binding site has been hampered both by lack of primary sequence and x-ray crystallographic information and by lack of a cDNA clone with which to do site-directed mutagenesis studies. Yeast (6) and rat liver (7) Fru-1,6-P2ase have also been reported to be regulated by cAMP-dependent phosphorylation. Phosphorylation of the rat liver enzyme at a site(s) located on a carboxyl-terminal extension unique to this form (8, 9 )t has been reported to increase enzyme activity (7, 10) , but the changes have not been universally observed (8) . Phosphorylation of the yeast enzyme, on the other hand, at an amino-terminal extension (11) results in a marked inhibition of activity (6) . Liver Fru-1,6-P2ase activity has been reported to increase during diabetes and starvation (12, 13) , suggesting that the enzyme is subject to long-term regulation at the levels of transcription and/or translation.
Since the DNA encoding mammalian enzyme had not been cloned and there was no information on the size, distribution, or concentration of its mRNA, we addressed these issues and report here the isolation and nucleotide sequence of a coding-length cDNA of rat liver Fru-1,6-P2ase, the complete amino acid sequence of the enzyme subunit, and data showing hormonal regulation of its mRNA. § EXPERIMENTAL PROCEDURES Materials. Fru-1,6-P2ase was purified to homogeneity from rat liver (7) and antibody to the purified enzyme was raised in New Zealand White rabbits (14) . Additional antisera to the rat and mouse liver enzymes, from rabbits and goats, were kind gifts of Bernard Horecker (Cornell University) and Frank Marcus Immunological Screening of Rat Liver cDNA in Agtl1. A Agtll recombinant cDNA rat liver library plated on Escherichia coli Y1090 cells was screened with Fru-1,6-P2ase antibody at a 1:1000 dilution of the rabbit antisera or a 1:500 dilution of the goat antiserum, essentially as described by Young and Davis (15) . After plaque purification of immunopositive clones, preliminary determination of the size of the insert(s) was obtained from the molecular mass of the fusion protein(s) (16, 17) .
Abbreviations: Fru-1,6-P2ase, fructose-1,6-bisphosphatase; Fru-2,6-P2, fructose 2,6-bisphosphate; PEPCK, phosphoenolpyruvate carboxykinase.
fRat kidney Fru-1,6-P2ase also lacks the carboxyl-terminal extension containing the cAMP-dependent phosphorylation site (M.R.E.-M. and S.J.P., unpublished results). §The sequence reported in this paper is being deposited in the EMBL/GenBank data base (IntelliGenetics, Mountain View, CA, and Eur. Mol. Biol. Lab., Heidelberg) (accession no. J04112).
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. DNA Sequencing. EcoRI restriction fragments of the cDNA were subcloned into the EcoRI site of the plasmid vector pEMBL18 (18) and sequenced by the chain-termination method (19) (20) . Tryptic or lysyl endoproteinase cleavage peptides of the enzyme were prepared and purified by reverse-phase HPLC (20) and their amino acid sequences were determined according to Hunkapillar et al. (21) with an Applied Biosystems model 470A gas-phase sequencer. The carboxyl-terminal residues of the enzyme were determined by carboxypeptidase Y digestion (20) .
RNA Blot Hybridization Analyses. Total cytoplasmic RNA, extracted from tissues with guanidinium isothiocyanate (22) , was denatured in the presence of formaldehyde and formamide and resolved by electrophoresis in 1% agarose gels in the presence of 18% formaldehyde before transfer to nylon membranes (23) . The membranes were dried briefly, heated at 80'C in a vacuum oven for 2 hr, and then prehybridized for 6 hr at 420C in 50% formamide/20 mM piperazine-N,N'-bis(2-ethanesulfonate), pH 6.4/80 mM NaCl/2 mM EDTA/0.5% NaDodSO4 containing sonicated salmon sperm DNA at 100 ,ug/ml. cDNA restriction fragments were 32P-labeled according to the random-primer method (24) by using a Multiprime kit (Amersham). The labeled probe was hybridized with the membranes at 42°C for 12-24 hr, after which the membranes were washed with four 500-ml washes of 15 mM NaCI/1.5 mM sodium citrate, pH 7.4/0.1% NaDodSO4 (30 min per wash) at 50°C. The membranes were then exposed to x-ray film for [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] hr with an intensifying screen at -70°C.
RESULTS
Nucleotide Sequence of a Coding-Length cDNA. Two cDNAs for rat hepatic Fru-1,6-P2ase were obtained by screening a rat liver cDNA library in Agtll with antisera raised against the purified enzyme. Immunoblot analyses of the expressed fusion proteins (data not shown) indicated that clone I (-134-kDa fusion peptide) coded for approximately half the enzyme subunit, whereas clone II (4160-kDa fusion peptide) was large enough to contain the entire enzyme subunit . EcoRI digestion of clone II (41300 bp) gave three fragments, z650, -500, and =150 bp long (data not shown). Each EcoRI fragment was subcloned into the plasmid vector and sequenced. Clone II was found to be a nearly full-length cDNA (full coding-length) and its complete nucleotide and deduced amino acid sequences are shown in Fig. 1 . The smallest restriction fragment (117 bp) included 12 bp of 5' untranslated region, the initiation codon, and the coding sequence for the first 34 amino acids. The mediumsized restriction fragment (472 bp) coded for amino acids . The largest fragment (666 bp) included codons for amino acids 192-362 (carboxyl terminus), the termination codon, and 151 bp of 3' untranslated region. The latter contained a polyadenylylation signal (AATAAA) followed by a stretch of 7 adenines at the end of the clone. To confirm the authenticity of the isolated clone, we compared the deduced amino acid sequence with that obtained from direct sequencing of a complete set of peptides generated by CNBr cleavage at methionine or by trypsin and lysyl endoproteinase digestion of the purified protein (Fig. 2) . The cDNA and protein sequences were in total agreement. In addition, the nucleotide-deduced sequence confirmed the alignment of five nonoverlapping peptides: those between lysyl endoproteinase peptides 3 and 4 ( Fig. 2, K3 and K4), 7 and 8, 8 and 9, 13 and 14, and 17 and 20.
Identification of the Blocked Amino Terminus of Fru-1,6-P2ase. Attempts to sequence the intact enzyme subunit or the first lysyl endoproteinase peptide did not yield any phenylthiohydantoin derivatives, confirming that the amino terminus of the rat liver enzyme is blocked (25) . The first lysyl endoproteinase peptide (Fig. 2, K1 ) was analyzed by fast atom bombardment mass spectrometry (20) . The (M+H)+ ion calculated from the amino acid sequence of K1 would be 2661.4 mass units; the (M+H)+ measured experimentally was 2703.6 mass units (data not shown). This difference of =42 mass units was attributed to N-acetylation of the peptide at the amino-terminal valine. Several fragment ions were noted at masses less than 2703.6 mass units, consistent with this proposed structure. Similar analysis of the first tryptic peptide [residues 1-16; calculated (M+H)+ of 1703 mass units] indicated an (M+H)+ of 1745 mass units (data not shown).
Identification of the Carboxyl Terminus of Fru-1,6-P2ase. Rittenhouse et al. (8) reported that the carboxyl-terminal sequence of the rat liver enzyme was Asp-Glu-Leu, which is one residue shorter than the sequence we found from sequencing the last lysyl endoproteinase peptide (Asp-GluLeu-Phe; Fig. 2, K19 ) and from the nucleotide-deduced residues preceding the termination codon (Fig. 1) . Substantiation of the sequence at the carboxyl terminus was obtained by digestion of the protein with carboxypeptidase Y; the first residue released was Phe, followed by Leu, Glu, and Asp (data not shown).
Tissue Distribution of Fru-1,6-P2ase mRNA and Effect of Diabetes. The distribution of the enzyme mRNA in various rat tissues was carried out by probing a gel blot of sizefractionated cytoplasmic RNA from liver, kidney, brain, heart, and skeletal muscle with a radiolabeled fragment ofthe rat liver cDNA. A single species of Fru-1,6-P2ase mRNA, about 1.4 kilobases (kb) long, was detected in liver (Fig. 3A , lane 1) and kidney (lane 2) RNA extracts but not in extracts from brain, heart, or skeletal muscle (lanes 3-5), even when hybridizations were done with 5 times the amount of RNA or at lower stringencies (data not shown).
Since Fru-1,6-P2ase activity is elevated in diabetes and decreased by insulin treatment (12, 13) , it was of interest to determine whether these changes are caused by changes in mRNA abundance. Fig. 3B shows the effect of alloxaninduced diabetes and insulin treatment on rat liver Fru-1,6-P2ase mRNA. There was a 10-fold increase in the level of enzyme mRNA from diabetic livers (lane 7) over control levels (lane 6) that was restored to normal only after 24 hr of insulin treatment (lane 9). The increase in Fru-1,6-P2ase mRNA paralleled that of the mRNA for PEPCK (26, 27) (lanes 6-9). However, insulin acted more rapidly to reduce PEPCK mRNA levels, which were reduced to control levels after only 6 hr of insulin treatment (lane 8). The changes in Fru-1,6-P2ase mRNA were coincident with changes in the enzyme's activity seen in extracts from livers of diabetic and insulin-treated diabetic rats (data not shown) (12, 13) .
DISCUSSION
The primary sequence of rat liver Fru-1,6-P2ase was deduced from the nucleotide sequence of a near-full-length clone and confirmed by direct sequencing of the purified protein ( Figs.  1 and 2 ). Fast atom bombardment mass spectrometry revealed that the amino-terminal valine was acetylated. There have been very few other reports of acetylated valine as the blocked amino-terminal residue (28) . Sheep liver and pig kidney bisphosphatases have acetylated threonine at their amino termini (29, 30) . A comparison of the amino-terminal sequences, putative allosteric and active-site regions, and Nucleotide and deduced amino acid sequences of Fru-1,6-P2ase cDNA. The nucleotide sequence of the coding strand of the cDNA is given in bold type and numbered in subscript. The internal EcoRI restriction sites are after bases 117 and 589, and the polyadenylylation signal is underlined. Shown above the nucleotide sequence is the deduced amino acid sequence (given in one-letter symbols and numbered above the residues), starting with the acetylated valine (*) and ending with phe-362 preceding the termination codon. carboxyl-terminal sequences of Fru-1,6-P2ases from rat liver, pig kidney, and yeast (Fig. 4) reveals a high degree of conservation, with an overall identity of =85% among the mammalian sequences. The similarity is even greater at the active and allosteric regions. For example, Lys-274, implicated in substrate binding (30, 31) , is conserved in all three primary sequences (refs. 30-33 and Fig. 4) , as are 92% of the amino acids in this active-site region of the enzyme subunit from all sources (residues 240-290) (30, 31, 33) . Lys-141 and Cys-128, reported to be involved in AMP binding and other allosteric behavior of the pig and rabbit enzymes (30, 31) , are also present in the rat liver form but not in that of yeast (32) (Fig. 4) . The retention of allosteric inhibition of yeast Fru-1,6-P2ase by AMP (33) without conservation of these residues casts some doubt on their role in aliosteric behavior of mammalian enzyme forms (34) . Our findings suggest that the secondary structure of rat liver Fru-1,6-P2ase may not be that different from those of other tissues and species (34) , but identification of allosteric and active-site domains with certainty must await crystallographic data.
The major difference between the rat liver and other mammalian enzymes is at the carboxyl terminus. The 27-residue carboxyl-terminal extension, unique to the rat liver enzyme, contains the cAMP-dependent phosphorylation site (Ser-341) (7, 8) as well as a second cAMP-dependent phosphorylation site (Ser-356) identified by Chattejee et al. (9) . As suggested by Rittenhouse et al. (8) , the absence of the entire carboxyl-terminal extension in the pig kidney and rabbit and sheep liver enzymes explains the inability of cAMP-dependent protein kinase to phosphorylate them.t It is interesting that glycolytic, gluconeogenic, and glycogenmetabolizing enzymes whose activities have been shown to be unequivocally affected by changes in their phosphorylation states have amino-terminal phosphorylation sites (35) (36) (37) (38) , including yeast Fru-1,6-P2ase (33), whereas those reported to undergo essentially "silent" phosphorylations, such as rat liver Fru-1,6-P2ase (39) and 6-phosphofructo-1-kinase (39), have carboxyl-terminal phosphorylation sites. X-ray crystallographic examination of the spatial relationship between the phosphorylation sites in these enzymes and the remainder of their respective subunits is necessary, however, before any generalized conclusion can be made.
An =1.4-kb species of Fru-1,6-P2ase mRNA was detected by hybridization with a fragment of the liver cDNA in liver Proc. Natl. Acad Sci. USA 85 (1988) Proc. Natl. Acad. Sci (Fig. 3A) but not in extracts from skeletal muscle, heart, or brain. The absence of a signal in the extracts from these tissues could either be due to the low abundance of Fru-1,6-P2ase mRNA or be due to the presence of a different form of the enzyme. However, the inability of anti-liver Fru-1,6-P2ase serum to crossreact with brain Fru-1,6-P2ase (40) and the finding of significant levels of Fru-1,6-P2ase activity in muscle (41) favor the latter explanation. The liver cDNA probe hybridized with the kidney mRNA in spite of the differences in the length and sequence at the carboxyl terminus of the respective enzymes (Fig. 4 and f) , suggesting that the two forms arose either by alternative RNA splicing or from different genes. In addition, posttranslational modification cannot be ruled out. On the other hand, Fru-1,6-P2ases from nongluconeogenic tissues such as brain and skeletal muscle are probably products of genes distinct from those found in liver and kidney. Isolation of a single Fru-1,6-P2ase gene species from a rat genomic library (M.R.E.-M. and S.J.P., unpublished work) by using the liver cDNA as a probe has confirmed the finding that other gene forms of the enzyme are not homologous with the liver cDNA.
Rat hepatic Fru-1,6-P2ase activity has been reported to increase in diabetes and starvation (12, 13) . Insulin administration to diabetic rats lowered liver Fru-1,6-P2ase activity to normal or subnormal levels (12) . Similar responses have been reported for liver cytosolic PEPCK and have been attributed to cAMP-dependent induction and insulin-dependent repression of its gene expression (26, 27) . cAMP acts to increase PEPCK mRNA by increasing the rate of gene transcription (26, 27) as well as decreasing the rate of mRNA degradation (41) . The results shown in Fig. 3B strongly suggest that the changes in Fru-1,6-P2ase activity result from changes in the amount of its cytoplasmic mRNA. These changes may be due to changes in transcription rates or in mRNA processing or degradation. The increase in Fru-1,6-P2ase mRNA in diabetes may result (i) from a decrease in insulin levels, which would otherwise repress mRNA synthesis or promote its degradation, or (ii) from an increase in cAMP concentration leading to induction ofenzyme mRNA or decreased mRNA degradation.
The slow decrease in Fru-1,6-P2ase mRNA upon insulin administration, relative to PEPCK mRNA, suggests that the half-life of the former may be longer. Insulin has been shown to affect mRNA abundance of a number of proteins involved in the hepatic gluconeogenic/glycolytic pathway, including PEPCK (26, 27, 42) , glucokinase (43) , and pyruvate kinase (44) . The results reported here add Fru-1,6-P2ase to the list of enzymes whose mRNA is regulated by insulin, and may Biochemistry: El-Maghrabi et al. provide another model for the study of insulin regulation of gene expression.
The availability of a coding-length cDNA for rat liver Fru-1,6-P2ase will not only facilitate studies on the mechanism of hormonal regulation of this key regulatory enzyme's gene expression but will also make possible the use of site-directed mutagenesis to investigate structure-function problems such as the location of the Fru-2,6-P2 binding site.
